Manufacturers Life Insurance Company, The Amylyx Pharmaceuticals, Inc. Transaction History

Manufacturers Life Insurance Company, The

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.71 - $19.57 $26,888 - $194,173	9,922 Added 11.58%	95,570 $271,000
Q4 2023 Feb 13, 2024	BUY	$12.07 - $18.46 $706,312 - $1.08 Million	58,518 Added 215.69%	85,648 $1.26 Million
Q3 2023 Nov 15, 2023	BUY	$18.08 - $23.45 $113,885 - $147,711	6,299 Added 30.24%	27,130 $496,000
Q2 2023 Aug 11, 2023	BUY	$20.98 - $31.42 $14,581 - $21,836	695 Added 3.45%	20,831 $449,000
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $2,299 - $3,397	83 Added 0.41%	20,219 $593,000
Q4 2022 Aug 11, 2023	SELL	$29.75 - $39.26 $2,469 - $3,258	-83 Reduced 0.41%	20,136 $744,000
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $599,046 - $790,539	20,136 New	20,136 $744,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.